388 related articles for article (PubMed ID: 27913543)
61. Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents.
Ananyeva NM; Lee TK; Jain N; Shima M; Saenko EL
Semin Thromb Hemost; 2009 Nov; 35(8):735-51. PubMed ID: 20169510
[TBL] [Abstract][Full Text] [Related]
62. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
Ragni MV
Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
[TBL] [Abstract][Full Text] [Related]
63. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
Szmurło D; Deryło Ł; Ryś P; Władysiuk M
Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
[TBL] [Abstract][Full Text] [Related]
64. Continuous infusion of coagulation factor concentrates during intensive treatment.
Holme PA; Tjønnfjord GE; Batorova A
Haemophilia; 2018 Jan; 24(1):24-32. PubMed ID: 28873263
[TBL] [Abstract][Full Text] [Related]
65. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors.
Pipe SW; Dunn AL; Young G
Expert Rev Hematol; 2023; 16(10):715-729. PubMed ID: 37602448
[TBL] [Abstract][Full Text] [Related]
66. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
Knight C; Danø AM; Kennedy-Martin T
Haemophilia; 2009 Mar; 15(2):405-19. PubMed ID: 19187191
[TBL] [Abstract][Full Text] [Related]
67. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
68. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.
Salaj P; Kubes R; Cetkovsky P; Capova I; Penka M; Ovesná P; Mesterton J; Lindgren P
Thromb Res; 2014 Feb; 133(2):162-7. PubMed ID: 24321420
[TBL] [Abstract][Full Text] [Related]
69. Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors.
Teitel JM
Transfus Apher Sci; 2018 Aug; 57(4):466-471. PubMed ID: 30093246
[TBL] [Abstract][Full Text] [Related]
70. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.
Ingerslev J; Sørensen B
Br J Haematol; 2011 Oct; 155(2):256-62. PubMed ID: 21895627
[TBL] [Abstract][Full Text] [Related]
71. Eptacog beta, a novel recombinant factor VIIa, for the treatment of hemophilia.
Watson N; Al-Samkari H
Drugs Today (Barc); 2022 Mar; 58(3):105-116. PubMed ID: 35274630
[TBL] [Abstract][Full Text] [Related]
72. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
[TBL] [Abstract][Full Text] [Related]
73. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
[TBL] [Abstract][Full Text] [Related]
74. Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven.
Johannessen M; Andreasen RB; Nordfang O
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):239-42. PubMed ID: 10870803
[TBL] [Abstract][Full Text] [Related]
75. Treatment of patients with haemophilia and inhibitory antibodies.
Giangrande PL
Indian J Pediatr; 2003 Aug; 70(8):655-9. PubMed ID: 14510087
[TBL] [Abstract][Full Text] [Related]
76. Monitoring inhibitor patients with the right assays.
Barrowcliffe TW
Semin Hematol; 2008 Apr; 45(2 Suppl 1):S25-30. PubMed ID: 18544420
[TBL] [Abstract][Full Text] [Related]
77. Bypassing agent prophylaxis for preventing arthropathy in patients with inhibitors.
Ewenstein BM; Wong WY; Schoppmann A
Haemophilia; 2010 Jan; 16(1):179-80. PubMed ID: 19702885
[No Abstract] [Full Text] [Related]
78. Unlabeled uses of factor VIIa (recombinant) in pediatric patients.
Hong I; Stachnik J
Am J Health Syst Pharm; 2010 Nov; 67(22):1909-19. PubMed ID: 21048207
[TBL] [Abstract][Full Text] [Related]
79. Successful eradication of inhibitor in a patient with severe haemophilia B and anaphylaxis to factor IX concentrates: is there a role for Rituximab and desensitization therapy?
Gamerman S; Singh AM; Makhija M; Sharathkumar A
Haemophilia; 2013 Nov; 19(6):e382-5. PubMed ID: 23992223
[No Abstract] [Full Text] [Related]
80. Safety update on recombinant factor VIIa in the treatment of congenital and acquired hemophilia.
Abshire T
Semin Hematol; 2008 Apr; 45(2 Suppl 1):S3-6. PubMed ID: 18544421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
